If you have been reading about peptide hormone and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-11-25. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C | Lyophilized peptide; protect from moisture and light. |
| Typical analytical method | HPLC and mass spectrometry | Used to confirm identity and estimate purity. |
| Common synonyms | AOD9604; hGH 176-191 | Naming varies by supplier and publication. |
| Disulfide bonds | One | Affects folded structure and stability. |
| Typical research purity | ≥95% | Value depends on supplier and analytical method. |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
Quality control for AOD-9604 involves verifying identity, purity, and concentration. Suppliers may provide a certificate of analysis listing HPLC purity and mass spectrometry data. Independent verification is advised because peptide products can vary in quality. Researchers should check for counterions, residual solvents, and microbial contamination. Proper documentation supports reproducibility and safety in laboratory studies. When sourcing, institutions often require third-party testing and detailed chain-of-custody records. These steps help ensure that experimental results are attributable to the peptide rather than impurities.
Analytical characterization of AOD-9604 typically employs reversed-phase high-performance liquid chromatography (RP-HPLC) to assess purity and identity. Mass spectrometry provides confirmation of molecular mass, while amino acid analysis can verify composition. These methods are standard for peptide research chemicals. Because the peptide lacks a distinct chromophore, detection often relies on ultraviolet absorbance at 214 nm or mass spectrometric response. Laboratories may also use capillary electrophoresis for separation. For example, size-exclusion chromatography can detect aggregates.
=== Vegetarian casings === Some innovative coextrusion processes have been developed in recent years, allowing 100% plant-based vegetarian casings to be created. Some special alginate coextrusion equipment is required to make casings that can be used in halal or kosher food making.
Even with all the potential benefits, the current applications of 242mAm are as yet hindered by the scarcity and high price of this particular nuclear isomer. In 2019, researchers at the UK National Nuclear Laboratory and the University of Leicester demonstrated the use of heat generated by americium to illuminate a small light bulb. This technology could lead to systems to power missions with durations up to 400 years into interstellar space, where solar panels do not function.
=== Heart attacks === The relative risk of ischemic cardiac events seen in pre-approval trials of rosiglitazone was similar to that of comparable drugs, but there was increased LDL cholesterol, LDL/HDL cholesterol ratio, triglycerides and weight. In 2005, at the insistence of the World Health Organization, GSK performed a meta-analysis of all 37 trials involving use of rosiglitazone, finding a hazard ratio of 1.29 (0.99 to 1.89). In 2006 the GSK updated the analysis, now including 42 trials and showing a hazard ratio of 1.31 (1.01 to 1.70). A large observational study comparing patients treated with rosiglitizone with patients treated with other diabetes therapies was performed at the same time and found a relative risk of 0.93 (95% C.I. 0.8 to 1.1) for those treated with rosiglitazone. The information was passed to the FDA and posted on the company website, but not otherwise published. GSK provided these analyses to the FDA, but neither the company nor the FDA warned prescribers or patients of the hazard. According to the FDA, the Agency did not issue a safety bulletin because the results of the meta analysis conflicted with those of the observational study and with the results of the ADOPT trial. A meta-analysis in May 2007 reported the use of rosiglitazone was associated with a 1.4 fold increased risk of heart attack and a numerically higher (but non-significant) increase in risk of death from all cardiovascular diseases against control. It contained 42 trials of which 27 were unpublished.
Osteoporosis and compromised bone mineral density (BMD) are significant conditions affecting the youth population. Weight-bearing physical activities are associated with bone development. Several studies have been made regarding different characteristics that affect bone development in youth such as gender, athletic status, type of exercise or sport, and intensity of exercise. A common way children today receive their daily dose of exercise is within their chosen sport. Sports can vary in their benefit of bone mineral composition and can be sorted into two categories: Osteogenic and Non-Osteogenic. Osteogenic sports are impact sports such as football, baseball, track and field, etc; while non-osteogenic sports are non-impact sports such as swimming or cycling. A study was done examining the relationship between jumping exercise interventions and non-osteogenic sport bone mineral content. The study showed that a 9-month jumping exercise plan can increase the bone mineral content of a non-osteogenic sport participant by 5.6%-12.6%. In conclusion, there is a strong correlation between physical activity and bone health in adolescents and physical activity should be a daily prescription in the lives of our youth today to maintain adequate bone health and development.
=== Podcasting === The Bowery Boys: New York City History is a New York history podcast started in 2007 by Tom Meyers and Greg Young, who were both living on the Lower East Side at the time next to the Bowery.
Sources: en.wikipedia.org
Props of the Gravity Gun and Portal Gun are popular items for both cosplayers and collectors. Notable examples include two film-quality replicas by Australian artist Harrison Krix, which were auctioned for charity in 2010 and 2011.
Scorched rice, known as hyeonmi cha in Korea Skullcap Shallot peel tea from Kalimantan Serendib (tea), tea from Sri Lanka Sobacha Spicebush (Lindera benzoin) leaves used to make a tea by some native peoples of eastern North America Spruce tea, made from needles of spruce trees Staghorn sumac, fruit can be made into a lemonade Stevia, can be used to make herbal tea, or as a sweetener in other beverages Sweet potato leaf tea, a common herbal tea in Chinese medicine Thyme, contains thymol Tulsi, or holy basil Turmeric tea Uncaria tomentosa, commonly known as cat's claw Valerian is used as a sedative, but clinical evidence for its psychoactive properties are inconclusive. Verbena (vervain) Wax gourd in East Asia and Southeast Asia. Wong Lo Kat, a recipe for herbal tea from Guangdong, China since the Qing Dynasty Woodruff Yarrow
=== Elderly === An increasing trend of anorexia among the elderly, termed "Anorexia of Aging", is observed, characterized by behaviors similar to those seen in typical anorexia nervosa but often accompanied by excessive laxative use. Most geriatric anorexia patients limit their food intake to dairy or grains, whereas an adolescent anorexic has a more general limitation. This eating disorder that affects older adults has two types – early onset and late onset. Early onset refers to a recurrence of anorexia in late life in an individual who experienced the disease during their youth. Late onset describes instances where the eating disorder begins for the first time late in life. The stimulus for anorexia in elderly patients is typically a loss of control over their lives, which can be brought on by many events, including moving into an assisted living facility. This is also a time when most older individuals experience a rise in conflict with family members, such as limitations on driving or limitations on personal freedom, which increases the likelihood of an issue with anorexia. There can be physical issues in the elderly that leads to anorexia of aging, including a decline in chewing ability, a decline in taste and smell, and a decrease in appetite. Psychological reasons for the elderly to develop anorexia can include depression and bereavement, and even an indirect attempt at suicide.
Cèpe bronzé ("dark cep"; Boletus aereus), much rarer than B. edulis, is more highly regarded by gourmets and consequently more expensive. Usually smaller than B. edulis, it is also distinctively darker in colour. It is especially suited to drying. Cèpe des pins ("pine tree cep"; Boletus pinophilus or Boletus pinicola) grows among pine trees. Rarer than B. edulis, it is less appreciated by gourmets than the two other kinds of porcini, but remains a mushroom rated above most others. Cèpe d'été ("summer cep"; Boletus reticulatus), also less common and found earlier. Molecular phylogenetic analyses have proven these three are all distinctive and separate species; other taxa formerly believed to be unique species or subspecies, such as B. betulicola, B. chippewaensis, B. persoonii, B. quercicola and B. venturii, are now known to be part of a B. edulis species complex with a wide morphological, ecological and geographic range, and that the genetic variability in this complex is low. Similar molecular technology has been developed to rapidly and accurately identify B. edulis and other commercially important fungi. Three divergent lineages found in Yunnan province in China that are commonly marketed and sold as B. edulis (and are actually more closely related to B. aereus) were described in 2013 as B. bainiugan, B. meiweiniuganjun and B. shiyong. The classification has since been updated and expanded. All lineages are still members of Boletus sect. Boletus, the sensu stricto "porcini clade" of the genus.
Sources: en.wikipedia.org
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.
The World Anti-Doping Agency classifies it as a prohibited peptide hormone. Athletes under anti-doping rules are not permitted to use it. Its presence can trigger a doping violation.
It is a fragment of growth hormone rather than a substance that signals the pituitary to release more hormone. Studies have not shown a consistent rise in IGF-1 or full growth hormone. Its metabolic effects, if any, appear separate from those of the complete hormone.
Yes, the World Anti-Doping Agency classifies AOD-9604 as a prohibited peptide hormone and related substance. Its use by athletes is banned under the relevant anti-doping code.